MARKET

CTXR

CTXR

Citius Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4730
-0.0002
-0.04%
Closed 16:00 12/06 EST
OPEN
0.4800
PREV CLOSE
0.4732
HIGH
0.4802
LOW
0.4660
VOLUME
66.56K
TURNOVER
--
52 WEEK HIGH
1.790
52 WEEK LOW
0.4000
MARKET CAP
10.44M
P/E (TTM)
-0.5744
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CTXR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CTXR News

  • The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
  • Benzinga.1d ago
  • Citius Pharmaceuticals to Present at the 12th Annual LD Micro Main Event
  • PR Newswire.3d ago
  • The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug
  • Benzinga.3d ago
  • Citius Pharmaceuticals Issues Corporate Update
  • PR Newswire.11/08 13:00

More

Industry

Pharmaceuticals
+0.45%
Pharmaceuticals & Medical Research
+0.49%

Hot Stocks

Name
Price
%Change

About CTXR

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.
More

Webull offers Citius Pharmaceuticals Inc (CTXR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.